CY1106733T1 - Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινη - Google Patents
Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινηInfo
- Publication number
- CY1106733T1 CY1106733T1 CY20071100943T CY071100943T CY1106733T1 CY 1106733 T1 CY1106733 T1 CY 1106733T1 CY 20071100943 T CY20071100943 T CY 20071100943T CY 071100943 T CY071100943 T CY 071100943T CY 1106733 T1 CY1106733 T1 CY 1106733T1
- Authority
- CY
- Cyprus
- Prior art keywords
- erythropoietin
- treatment
- fructopyranoses
- neurological dysfunction
- dysfunction including
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title abstract 2
- 108090000394 Erythropoietin Proteins 0.000 title abstract 2
- 229940105423 erythropoietin Drugs 0.000 title abstract 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 2
- 230000009251 neurologic dysfunction Effects 0.000 title 1
- 208000015015 neurological dysfunction Diseases 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 238000011970 concomitant therapy Methods 0.000 abstract 1
- -1 fructopyranose sulfamates Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26619401P | 2001-02-02 | 2001-02-02 | |
| PCT/US2002/003096 WO2002064085A2 (en) | 2001-02-02 | 2002-01-24 | Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1106733T1 true CY1106733T1 (el) | 2012-05-23 |
Family
ID=23013568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20071100943T CY1106733T1 (el) | 2001-02-02 | 2007-07-13 | Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινη |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6908902B2 (https=) |
| EP (1) | EP1471871B1 (https=) |
| JP (1) | JP2005501801A (https=) |
| KR (1) | KR100896971B1 (https=) |
| AT (1) | ATE361089T1 (https=) |
| CA (1) | CA2437333A1 (https=) |
| CY (1) | CY1106733T1 (https=) |
| DE (1) | DE60219961T8 (https=) |
| DK (1) | DK1471871T3 (https=) |
| ES (1) | ES2284858T3 (https=) |
| MX (1) | MXPA03006952A (https=) |
| NO (1) | NO20033440L (https=) |
| NZ (1) | NZ548578A (https=) |
| PT (1) | PT1471871E (https=) |
| RU (1) | RU2317086C2 (https=) |
| WO (1) | WO2002064085A2 (https=) |
| ZA (1) | ZA200306818B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
| US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
| DK1471871T3 (da) * | 2001-02-02 | 2007-09-17 | Ortho Mcneil Pharm Inc | Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin |
| CA2459146A1 (en) * | 2001-08-30 | 2003-03-13 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
| WO2003103608A2 (en) * | 2002-06-11 | 2003-12-18 | The Burnham Institute | Neuroprotective synergy of erythropoietin and insulin-like growth factor |
| US20030235576A1 (en) * | 2002-06-15 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New drug combinations for the treatment of ischaemic conditions |
| DE10226814A1 (de) * | 2002-06-15 | 2004-01-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände |
| ATE360415T1 (de) * | 2002-09-17 | 2007-05-15 | Motac Neuroscience Ltd | Behandlung von dyskinesie |
| EP1815854A1 (en) * | 2002-09-17 | 2007-08-08 | Motac Neuroscience Limited | Treatment of dyskenesia |
| US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| AT500929B1 (de) | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
| WO2007020922A1 (ja) * | 2005-08-17 | 2007-02-22 | Chugai Seiyaku Kabushiki Kaisha | 脳疾患の治療剤および予防剤 |
| US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
| US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| WO2008022349A2 (en) | 2006-08-18 | 2008-02-21 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| US8603980B2 (en) | 2007-01-16 | 2013-12-10 | The Johns Hopkins University | Glutamate receptor antagonists and methods of use |
| WO2008137066A1 (en) * | 2007-05-02 | 2008-11-13 | The Board Of Regents Of The University Of Oklahoma | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
| RU2335296C1 (ru) * | 2007-06-26 | 2008-10-10 | Сергей Марович Дудкин | Фармацевтическая композиция для профилактики и лечения неврологических заболеваний |
| AU2008282496B2 (en) | 2007-07-27 | 2013-04-04 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-iduronidase activity in the CNS |
| WO2009143268A2 (en) * | 2008-05-22 | 2009-11-26 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
| US20090304789A1 (en) * | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
| CA2748889A1 (en) | 2009-03-18 | 2010-09-23 | Armagen Technologies, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
| JP2013507131A (ja) | 2009-10-09 | 2013-03-04 | アーメイゲン・テクノロジーズ・インコーポレイテッド | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
| AU2012346448B2 (en) | 2011-12-02 | 2017-09-14 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| WO2013139292A1 (zh) | 2012-03-23 | 2013-09-26 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种含辛弗林和托吡酯的联合产品 |
| CN103316026B (zh) | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
| CN102579367B (zh) | 2012-03-23 | 2014-03-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 托吡酯缓释药物组合物、其制备方法及用途 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| DK173067B1 (da) | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
| US5242942A (en) | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
| US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5384327A (en) | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| JPH09501418A (ja) | 1993-07-19 | 1997-02-10 | アムジエン・インコーポレーテツド | エアゾル化タンパク質の安定化 |
| US5571787A (en) | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
| US5700909A (en) | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
| CN1057534C (zh) | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | 促红细胞生成素类似物 |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
| DK0736029T3 (da) * | 1993-12-23 | 2006-05-15 | Ortho Mcneil Pharm Inc | Antikonvulsive pseudofructopyranosesulfamater |
| IL116085A (en) | 1994-12-16 | 1999-12-31 | Ortho Pharma Corp | Spray dried erythropoietin |
| US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| AU3501697A (en) | 1996-06-28 | 1998-01-21 | Ortho Pharmaceutical Corporation | Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration |
| US5753694A (en) | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
| EP1731174A3 (en) | 1996-08-02 | 2007-01-17 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond |
| EP0986644B1 (de) | 1997-07-23 | 2006-10-04 | Boehringer Mannheim GmbH | Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren |
| ES2208798T3 (es) | 1997-09-01 | 2004-06-16 | Aventis Pharma Deutschland Gmbh | Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso. |
| US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| CA2327095A1 (en) * | 1998-04-02 | 1999-10-14 | Avicena Group, Inc. | Compositions containing a combination of a creatine compound and a second agent |
| ATE339507T1 (de) | 1998-06-15 | 2006-10-15 | Gtc Biotherapeutics Inc | Erythropoietin-analog-menschliches serum-albumin fusionsprotein |
| WO2000061138A1 (en) * | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders |
| AU784550B2 (en) * | 1999-04-13 | 2006-05-04 | Kenneth S. Warren Institute, Inc., The | Modulation of excitable tissue function by peripherally administered erythropoietin |
| CA2270795A1 (en) * | 1999-05-05 | 2000-11-05 | Gestilab Inc. | Neuroprotective compositions and uses thereof |
| DK1471871T3 (da) * | 2001-02-02 | 2007-09-17 | Ortho Mcneil Pharm Inc | Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin |
-
2002
- 2002-01-24 DK DK02724904T patent/DK1471871T3/da active
- 2002-01-24 KR KR1020037010232A patent/KR100896971B1/ko not_active Expired - Fee Related
- 2002-01-24 PT PT02724904T patent/PT1471871E/pt unknown
- 2002-01-24 MX MXPA03006952A patent/MXPA03006952A/es active IP Right Grant
- 2002-01-24 ES ES02724904T patent/ES2284858T3/es not_active Expired - Lifetime
- 2002-01-24 CA CA002437333A patent/CA2437333A1/en not_active Abandoned
- 2002-01-24 JP JP2002563882A patent/JP2005501801A/ja not_active Ceased
- 2002-01-24 EP EP02724904A patent/EP1471871B1/en not_active Expired - Lifetime
- 2002-01-24 AT AT02724904T patent/ATE361089T1/de active
- 2002-01-24 NZ NZ548578A patent/NZ548578A/en not_active IP Right Cessation
- 2002-01-24 US US10/056,828 patent/US6908902B2/en not_active Expired - Lifetime
- 2002-01-24 DE DE60219961T patent/DE60219961T8/de active Active
- 2002-01-24 RU RU2003124059/14A patent/RU2317086C2/ru not_active IP Right Cessation
- 2002-01-24 WO PCT/US2002/003096 patent/WO2002064085A2/en not_active Ceased
-
2003
- 2003-08-01 NO NO20033440A patent/NO20033440L/no not_active Application Discontinuation
- 2003-09-01 ZA ZA2003/06818A patent/ZA200306818B/en unknown
-
2005
- 2005-01-31 US US11/047,420 patent/US20050261182A1/en not_active Abandoned
-
2007
- 2007-07-13 CY CY20071100943T patent/CY1106733T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60219961T8 (de) | 2008-04-17 |
| EP1471871B1 (en) | 2007-05-02 |
| EP1471871A4 (en) | 2005-11-09 |
| US20050261182A1 (en) | 2005-11-24 |
| NZ548578A (en) | 2008-03-28 |
| NO20033440D0 (no) | 2003-08-01 |
| KR20040011458A (ko) | 2004-02-05 |
| CA2437333A1 (en) | 2002-08-22 |
| US20020169109A1 (en) | 2002-11-14 |
| JP2005501801A (ja) | 2005-01-20 |
| DE60219961D1 (de) | 2007-06-14 |
| NO20033440L (no) | 2003-09-29 |
| EP1471871A2 (en) | 2004-11-03 |
| MXPA03006952A (es) | 2004-10-15 |
| WO2002064085A3 (en) | 2004-09-10 |
| US6908902B2 (en) | 2005-06-21 |
| PT1471871E (pt) | 2007-06-05 |
| ZA200306818B (en) | 2005-02-23 |
| DE60219961T2 (de) | 2008-01-17 |
| DK1471871T3 (da) | 2007-09-17 |
| RU2317086C2 (ru) | 2008-02-20 |
| RU2003124059A (ru) | 2005-01-27 |
| ATE361089T1 (de) | 2007-05-15 |
| WO2002064085A2 (en) | 2002-08-22 |
| ES2284858T3 (es) | 2007-11-16 |
| KR100896971B1 (ko) | 2009-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106733T1 (el) | Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινη | |
| EE05417B1 (et) | Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias | |
| AR037109A1 (es) | Uso de flibanserina | |
| EE200300212A (et) | Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks | |
| BR0309665A (pt) | Tratamento de deficiência de alfa-galactosidase a | |
| CY1110570T1 (el) | Χρηση της ουριδινης σε συνδυασμο με χολινη για τη θεραπεια διαταραχων της μνημης | |
| EP1274444A4 (en) | COMPOUNDS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS OR DISORDERS CAUSED BY THE ABUSE OF PSYCHOACTIVE SUBSTANCES | |
| NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
| DE60206512D1 (de) | Rapanycin29-enole | |
| PT1073658E (pt) | Inibidores de ogmp pdes de pirazolopirimidinona para o tratamento da disfuncao sexual | |
| PT1485127E (pt) | Administração de agentes para o tratamento de inflamação | |
| BR0110028A (pt) | Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica | |
| DE60239931D1 (de) | Kombinationstherapie | |
| DE602004032522D1 (de) | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung | |
| MXPA03003632A (es) | Metodo para tratamiento de tumores usando terapia de combinacion. | |
| ITBO20000453A0 (it) | Apparecchiatura e procedimento per la sterilizzazione del terreno . | |
| TR200101149T2 (tr) | Dış retina bozukluklarının tedavisi. | |
| ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
| DK1133296T3 (da) | Ny terapeutisk anvendelse af nicergolin | |
| BR0015938A (pt) | Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa | |
| WO2002039958A3 (en) | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents | |
| NO20005548D0 (no) | Mykobakterieinhibitorer | |
| ES1034986Y (es) | Aparato para el tratamiento del cuerpo humano. | |
| DE60124093D1 (de) | S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen. | |
| DK1235573T3 (da) | Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme |